In this issue of JAMA, the US Preventive Services Task Force (USPSTF) presents a Recommendation Statement1 and an accompanying Evidence Report2 that consider the risks and benefits of menopausal hormone therapy for primary prevention of chronic conditions and arrive at a grade D recommendation.1 The recommendations are based only on evidence from randomized trials and do not pertain to women considering hormone therapy for vasomotor symptoms, given the USPSTF mandate to consider specific preventive care services for patients without related signs and symptoms of illness.
Lewis CE, Wellons MF. Menopausal Hormone Therapy for Primary Prevention of Chronic Disease. JAMA. 2017;318(22):2187–2189. doi:10.1001/jama.2017.16974
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: